Atai Life Sciences(ATAI) Company, the depression treatment drug 'BPL‑003' enters Phase 3 clinical trials… approved as an FDA Breakthrough Therapy

Clinical-stage biotech company AtaiBeckley (ATAI) is refining its pre-Phase 3 development and commercialization strategy for its treatment-resistant depression (TRD) drug “BPL‑003.” The company announced it has successfully completed a End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and plans to initiate two pivotal Phase 3 trials in Q2 2026.

AtaiBeckley disclosed its key clinical, regulatory, and business strategies during the “2026 Virtual Investor Day” held online on the 10th (local time), and provided updates on its R&D pipeline progress. The company highlighted the upcoming Phase 3 trials for “BPL‑003,” commercialization preparations, and pipeline development as major achievements.

The core pipeline candidate BPL‑003 is a nasal spray based on melatonin benzoate. It has received FDA Breakthrough Therapy designation and showed positive results in a Phase 2b trial for treatment-resistant depression. The study demonstrated rapid antidepressant effects within two days of a single dose, with symptom improvements lasting about eight weeks. Additionally, in an open-label extension study, patients receiving a second dose showed further improvements in response and remission rates.

Based on these results, the company plans to launch two parallel Phase 3 trials named “ReConnection‑1” and “ReConnection‑2” in Q2 2026. These will be 12-week randomized, double-blind, placebo-controlled studies, followed by a 52-week open-label extension allowing re-dosing based on patient response.

Co-founder and CEO Srinivas Rao stated, “BPL‑003 has demonstrated rapid and sustained antidepressant effects. Based on positive feedback from the FDA after Phase 2, we plan to start two Phase 3 trials in Q2 2026.” He further emphasized, “With Breakthrough Therapy designation and robust clinical trial design, this drug has the potential to significantly change the treatment landscape for TRD.”

AtaiBeckley also announced its commercialization strategy. The company explained that BPL‑003 is designed to naturally integrate into existing “interventional psychiatry” treatment frameworks. Specifically, the strategy leverages established clinic operation models, such as Johnson & Johnson’s depression treatment drug “Spravato,” to improve patient access and operational efficiency simultaneously.

Kavita Pankaj, Senior Vice President of New Product Planning and Early Commercialization, explained, “Patients need a treatment that acts quickly and does not require major changes to their daily routines. With its short treatment duration and intermittent dosing, BPL‑003 offers a practical model for clinics to treat more patients more efficiently.”

The event also featured a panel discussion on changes in the mental health treatment environment. Participants included Dr. Peter Hendricks from the University of Alabama at Birmingham School of Public Health, Dr. David Pfeiffer, Professor of Psychiatry at UC San Diego, and Dr. Samuel Wilkinson, Associate Professor of Psychiatry at Yale School of Medicine. They discussed barriers to treating TRD and the role of next-generation therapies.

The panel emphasized that developing new treatment approaches—such as reducing treatment time and enabling intermittent dosing—is crucial for increasing patient access. Additionally, with the expanded use of therapies like Spravato, the infrastructure for interventional psychiatry has been substantially established, suggesting that next-generation drugs like BPL‑003 could quickly establish a clinical foothold.

Meanwhile, the company highlighted its financial stability. With current cash holdings, operations are expected to be funded at least until early 2029, sufficient to support ongoing R&D until the main data from the two Phase 3 trials are available.

The pipeline continues to expand. The social anxiety disorder candidate “EMP‑01” recently showed positive results in a Phase 2a trial, and the drug “VLS‑01” for TRD is expected to report key Phase 2 results in the second half of 2026. Industry analysts believe that with these clinical achievements, AtaiBeckley is well-positioned to establish itself as a next-generation mental health treatment platform in the field of interventional psychiatry.